Journal, university investigations launched into gene-editing death following Science-Retraction Watch reporting

Nature is investigating concerns surrounding a paper at the heart of a news story published last week on the death of a 6-year-old girl following a gene therapy treatment in China.

The paper, published in February by a team led by neuroscientist Zilong Qiu of Shanghai Jiao Tong University School of Medicine in China, described preclinical work for a gene-editing treatment for Snijders Blok-Campeau syndrome, a neurodevelopmental disorder. 

As we reported in collaboration with Science, the work was funded in part by the family of a 6-year-old girl with the condition. The family had approached Qiu based on work he had done with gene therapy for Rett syndrome, a disorder that also causes developmental delay. The parents ended up paying $860,000 to fund preclinical work for a gene-editing treatment for their daughter, who died of a severe immune reaction to the therapy seven days after receiving it. 

Continue reading Journal, university investigations launched into gene-editing death following Science-Retraction Watch reporting

Just over 400 U.S. patents contain citations to retracted scientific papers

Surendra/Adobe Stock

Around 400 U.S. patents contain at least one citation to a retracted scientific paper, a new study has found. 

The analysis, posted last month to the preprint server SSRN, analyzed granted patents in the United States in PatentsView, a database developed by the United States Patent and Trademark Office (USPTO) using artificial intelligence algorithms, and the Retraction Watch Database. 

Of the more than 13 million patents in the USPTO database, 136,162 contained citations to at least one scientific paper. Of these, 401 patents cited retracted papers: 195 cited the retracted paper before it was filed, 92 cited papers retracted while being examined, and 114 cited a paper that was retracted after the patent was granted, the study revealed. 

Continue reading Just over 400 U.S. patents contain citations to retracted scientific papers

Kaggle removes problematic stroke dataset for copyright infringement 

Images from the now-deleted dataset on Kaggle purportedly showed people who had a stroke, but the folder included stock images and photos of politicians and celebrities, as seen in this screenshot.

The online data repository Kaggle has removed a problematic dataset for violating intellectual property rights months after it was flagged by sleuths for containing celebrity photos and lacking information on data provenance or confirmed medical diagnoses. 

Researchers had used the images to train machine learning algorithms to detect stroke, but the dataset instead contained images of people with Bell’s palsy — as well as pictures of celebrities from movies and on the red carpet, as we reported in May. Adrian Barnett, a medical statistician at Queensland University of Technology in Australia, flagged the dataset after discovering two others he and his colleagues investigated in a February preprint that showed signs of being fabricated. 

Using a reverse image search, Barnett matched four of the photos in the dataset, called “Facial droop and facial paralysis image,” to a paper published years earlier in the Journal of the Canadian Dental Association (JCDA). Only after prompting the journal to complain to Kaggle did the company take down the dataset. 

Continue reading Kaggle removes problematic stroke dataset for copyright infringement 

Exclusive: News outlet killed story on plagiarism allegations after Cambridge prof hired law firm

Jason Arday

In September 2025, Times Higher Education had a bombshell story in the works: A star sociology professor at the University of Cambridge had allegedly plagiarized parts of his Ph.D. thesis and several journal articles. In one of the articles, the borrowed text appeared in quotes from subjects the professor, Jason Arday, claimed to have interviewed himself. 

But after Arday enlisted Carter-Ruck, one of the United Kingdom’s leading defamation law firms, to send Times Higher Education a letter, the publication spiked the story, according to three sources who spoke to Retraction Watch.

One of the sources was David Sanders, a biochemist at Purdue University in Indiana, and a sleuth who contributes to the Times Higher Education on topics related to academic misconduct. He reviewed a 63-page dossier of text comparisons prepared by the publication last year and came back with his own findings. “There is no question that there is extensive plagiarism,” Sanders told us.

Continue reading Exclusive: News outlet killed story on plagiarism allegations after Cambridge prof hired law firm

Journal investigating apparent data mismatch in climate study

A leading environmental economics journal is looking into claims that a 2025 study linking national innovation to lower carbon emissions contains data that does not match its source, after an expert in the field requested the paper be retracted. 

The article appeared in Ecological Economics, the journal for the International Society for Ecological Economics and published by Elsevier. The authors, three researchers at ESSCA School of Management in Lyon, claimed to draw on data from 229 countries between 2013 and 2020 and reported a negative relationship between a country’s “innovativeness” and its carbon dioxide emissions per capita. The paper has been cited five times, according to Clarivate’s Web of Science. 

But three months after it was published, in October 2025, the journal began investigating anomalies in the dataset, although the authors maintain none of it was fabricated. In a letter to the journal’s editors requesting a retraction last October, seen by Retraction Watch, an academic with expertise in the field who reviewed the dataset said the paper had “serious data integrity concerns” and described a “clear case of research misconduct.” 

Continue reading Journal investigating apparent data mismatch in climate study

Weekend reads: Young girl’s death after gene therapy never made public; FDA retracts lettuce test result; ADA delays editorial publication after controversy

If your week flew by — we know ours did — catch up here with what you might have missed.

The week at Retraction Watch featured:

In case you missed the news, the Hijacked Journal Checker now has more than 450 entries. The Retraction Watch Database has over 66,000 retractions. Our list of COVID-19 retractions is up to 650, and our mass resignations list has more than 50 entries. We keep tabs on all this and more. If you value this work, please consider showing your support with a tax-deductible donation. Every dollar counts.

I Support Retraction Watch

Here’s what was happening elsewhere (some of these items may be paywalled, metered access, or require free registration to read):

Continue reading Weekend reads: Young girl’s death after gene therapy never made public; FDA retracts lettuce test result; ADA delays editorial publication after controversy

Editors of economics journal resign after association renews Taylor & Francis contract

Forty-one editors, associate editors and advisory board members resigned from their roles at the Review of Social Economy after the Association for Social Economics, which owns the journal, renewed its contract with publisher Taylor & Francis. 

The resigning members, who cited concerns the publisher would eventually transition the journal to a model based wholly on author publishing fees as a reason for their departure, say they plan to launch their own publication. ASE, however, denies the journal plans to fully rely on author publishing charges. 

The four coeditors of the journal resigned on July 4, according to an email to the ASE we have seen. Former editor Roberto Veneziani, economics professor at Queen Mary University of London, said that happened two days after the association decided to renew its contract with Taylor & Francis. On July 10, 37 associate editors and advisory board members also resigned, noting they shared the values of the coeditors. 

Continue reading Editors of economics journal resign after association renews Taylor & Francis contract

Exclusive: A couple paid more than $800,000 for a gene-editing therapy for their daughter. She died, and it wasn’t made public

Illustration: Daria Lada

An investigation by Science and Retraction Watch has uncovered details about a clinical trial that resulted in the death of its sole patient: a 6-year-old girl with a rare genetic mutation affecting her cognitive development. Her death has never been reported publicly, even though the medical team published its preclinical work in Nature earlier this year. Also omitted from the paper and trial records: The family paid more than $800,000 to fund the therapy’s development. The family has asked the authors to withdraw the paper, and experts we spoke to raised issues they say may warrant a retraction. The beginning of the story, by Retraction Watch contributing writer Brendan Borrell, is below, lightly edited for brevity. Read the full story at Science.  

The 6-year-old girl tugged on her mother’s hand as they pressed through the doors of the hospital in Shanghai. Behind them, her father rolled a large suitcase with everything the child needed for the weeklong stay. She told her parents it felt like they were going on vacation. In fact, they brought her here for an experimental gene therapy. 

The girl was slipping behind her peers in kindergarten. She still spoke in simple sentences and ate with training chopsticks. Underneath it all was a single mutated DNA base, a T that should have been a C.

“Your ‘book’ has a small mistake, which has caused you to have a disease that affects your growth,” read the children’s version of the informed consent form from the hospital. “Over time, it can get more serious.” 

Doctors hoped to repair that mistake while her brain was still building itself. It would be a clinical trial of one, funded in part by $860,000 the parents had scraped together from their own savings and from relatives.

Continue reading Exclusive: A couple paid more than $800,000 for a gene-editing therapy for their daughter. She died, and it wasn’t made public

Journal retracts breast cancer paper 10 years after sleuth flagged issues

A biomedical journal has retracted a paper by a cancer researcher who sued her former institution over misconduct allegations. The action comes a decade after a sleuth first raised concerns about the article.

Former Ohio State researcher Flavia Pichiorri criticized how the publication, the Journal of Experimental Medicine, handled the dispute and said the journal suddenly pivoted away from its plan to republish the study with repeated experiments, a claim supported by correspondence seen by Retraction Watch.    

In 2020, Ohio State University found Pichiorri, who worked in the lab of Carlo Croce, culpable for manipulating and reusing images in four publications, spanning from her time in Croce’s lab through establishing her own lab at Ohio State. Croce was cleared of direct misconduct, but OSU found serious management and oversight failures in his laboratory. Once a high-profile cancer researcher at Ohio State, Croce now has 18 retractions. He has filed several defamation lawsuits unsuccessfully, and reportedly owes his attorneys more than $1 million. 

Continue reading Journal retracts breast cancer paper 10 years after sleuth flagged issues

Exclusive: Medical student in Nepal behind busy research factory

A second-year medical student in Nepal is at the center of an international research network churning out everything from systematic reviews and meta-analyses to case reports and database studies, Retraction Watch has learned.

The student, Raghabendra Kumar Mahato, leverages this network, which includes nearly 1,000 members connected through the WhatsApp messaging platform, to produce large numbers of conference abstracts and journal papers at breakneck speed, according to posts and messages we have reviewed. The work has been presented or accepted for presentation at conferences organized by the American Heart Association (AHA), the European Society for Medical Oncology (ESMO) and many other medical societies and has appeared in journals from major publishers.

But a review of dozens of WhatsApp messages we obtained and an interview with a disillusioned member of the community, called the “Global Clinical Research Consortium,” suggests the network produces fast-churn science, includes a known paper miller and treats authorship as a tradable commodity.

Continue reading Exclusive: Medical student in Nepal behind busy research factory